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We evaluated prevalence and clinical outcome of polyvascular disease (PolyVD) in patients presenting with acute coronary
syndrome (ACS). Data for 7689 consecutive ACS patients were collected from the 2nd Gulf Registry of Acute Coronary Events
between October 2008 and June 2009. Patients were divided into 2 groups (ACS with versus without PolyVD). All-cause mortality
was assessed at 1 and 12 months. Patients with PolyVD were older and more likely to have cardiovascular risk factors. On
presentation, those patients were more likely to have atypical angina, high resting heart rate, high Killip class, and GRACE
risk scoring. They were less likely to receive evidence-based therapies. Diabetes mellitus, renal failure, and hypertension were
independent predictors for presence of PolyVD. PolyVD was associated with worse in-hospital outcomes (except for major
bleedings) and all-cause mortality even after adjusting for baseline covariates. Great eﬀorts should be directed toward primary
and secondary preventive measures.
1.Introduction
Atherothrombosis is a systemic disease that often occurs at
more than one vascular site and should be considered in
practice as an integral disease [1–3]. Moreover, patients with
aﬀected arterial disease are more likely to develop higher
eventratesthanpatientswithmultipleriskfactorsonly[3,4].
Polyvascular disease (PolyVD) deﬁned as presence of more
than one aﬀected vascular bed, that is, any combination
of the following: coronary artery disease (CAD), peripheral
arterial disease (PAD), and cerebrovascular disease (CVD)
[5–9]. The frequency and impact of PolyVD in patients with
acute coronary syndrome (ACS) in the Gulf region of the
Middle East have not been studied yet. These countries have
higher prevalence of the traditional risk factors in a unique
fashion [1]. The aim of the current study is to evaluate the2 The Scientiﬁc World Journal
prevalenceofPolyVDanditsimpactonthein-hospitalmajor
adverse events and 1-year mortality across ACS in a Middle
Eastern population.
2. Methods
2.1. Study Population. Data were collected from a prospec-
tive, multicenter study of the 2nd Gulf Registry of Acute
Coronary Events (Gulf RACE-2) between October 2008 and
June 2009. We recruited 7,930 consecutive patients with ACS
from 6 adjacent Middle Eastern Gulf countries (Bahrain,
Kingdom of Saudi Arabia, Qatar, Oman, United Arab Emi-
rates, and Yemen). Patients diagnosed with ACS, including
unstableangina(UA)andnon-ST-andST-elevationmyocar-
dial infarction (NSTEMI and STEMI, resp.), were enrolled
from 65 hospitals. On-site cardiac catheterization laboratory
was available in 43% of the participating hospitals. All
prospective patients with ACS were eligible for enrollment.
The study received ethics approval from the institutional
review boards in all participating hospitals. Full details of the
methods have been previously published [10].
2.2. Deﬁnitions. ACS: diagnosis of the diﬀerent types of
ACS and deﬁnitions of data variables were based on the
American College of Cardiology clinical data standards [10,
11]. Peripheral arterial disease (PAD): deﬁned as presence of
any of the following: intermittent claudication, critical limb
ischemia (ulcerorgangrene),peripheralbypass surgery(sur-
gical bypass for PAD indication), or peripheral percutaneous
transluminal angioplasty. Polyvascular disease (PolyVD) was
deﬁned as presence of more than one aﬀected vascular bed,
that is, CAD, cerebrovascular disease (CVD), and asymp-
tomaticorsymptomaticperipheralarteries(PAD)[6].Acase
report form (CRF) for each patient with suspected ACS was
ﬁlled out upon hospital admission by assigned physicians
and/or research assistants using standard deﬁnitions and
was completed throughout the patient’s hospital stay. All
CRFs were veriﬁed by a cardiologist then sent online to the
principal coordinating center, where the forms were further
checked for mistakes before submission for ﬁnal analysis.
2.3. Statistical Analysis. Data are presented as proportions
or mean ± standard deviation (SD) as appropriate. Baseline
demographic characteristics, past medical history, clinical
presentation, and clinical outcomes were compared between
2groups(ACSwithversuswithoutPolyVD).Subanalysiswas
performed comparing the clinical outcomes among various
combinations of vascular bed aﬀection (ACS alone, ACS
plus PAD, ACS plus CVD, and ACS plus PAD and CVD).
Statistical analyses were conducted using the Student’s t-test
for continuous variables and Pearson chi-square (χ2)t e s tf o r
categorical variables. Primary endpoints included recurrent
ischemia, heart failure (HF), stroke, major bleedings, and
mortality. All-cause mortality was assessed at 1-month and
12-month follow-up period. In order to assess the indepen-
dent association of PolyVD with clinical outcomes, logistic
regression analysis models were used and crude and adjusted
odd ratios were calculated. We included signiﬁcant baseline
variables in the analysis such as age, sex, diabetes mellitus,
hypertension, dyslipidemia, smoking, renal failure, prior
coronary artery disease and prior coronary revascularization
in addition to the type of ACS at presentation. Univariate
and multivariate analysis for clinical outcomes were tested.
Global Registry of ACS events (GRACE) risk scores for
hospital mortality were used to stratify the risk status of
patients at presentation as low, intermediate, or high [12].
All P values were the results of 2-tailed tests and values <0.05
were considered signiﬁcant. Data analysis was carried out
using the Statistical Package for Social Sciences version 18
(SPSS Inc., USA).
3. Results
3.1. Clinical and Biochemical Proﬁles. Out of the 7689
patients who were admitted with ACS, PolyVD was docu-
mented in 428 patients (5.6%) in terms of ACS plus PAD
(110 patients), ACS plus CVD (284 patients), and ACS plus
PAD and CVD (34 patients). Table 1 shows the baseline
characteristics and risk factors of patients with PolyVD
includingACSincomparisontoACS-alonepatients.Patients
w i t hP o l y V Dw e r e6y e a r so l d e r( 6 2± 11 versus 56 ± 12,
P<0.0001) and were more likely to be female (31% versus
20%, P = 0.001). PolyVD patients were more likely to have
risk factors such as diabetes mellitus (67% versus 38%,
P = 0.001), hypertension (78% versus 45%, P = 0.001),
dyslipidemia (55% versus 36%, P = 0.001), and renal failure
(14% versus 3%, P = 0.001). They were less likely to be
smokers (45% versus 54%, P = 0.001). On presentation with
ACS, PolyVD patients had higher heart rate, and GRACE
risk score and were more likely to present with a higher
Killip class (P = 0.001 for all). NSTEACS was the most
frequent diagnosis in PolyVD patients whereas STEMI was
the predominant diagnosis in ACS-alone group.
3.2. In-Hospital Treatment Pattern. Table 2 demonstrates the
treatment pattern for patients with and without PolyVD.
In regard to on-admission therapy, there were no diﬀer-
ences between the two groups in the use of heparin and
glycoprotein inhibitors. Apart from thrombolysis therapy
use that was in favor of ACS-alone group, patients with
PolyVD were more likely to be treated with oral antiplatelet,
angiotensin-converting enzyme inhibitors, statin, and β-
blockers. Coronary intervention was more frequently used in
ACS-alonegroupincomparisontoPolyVDpatients.Aspirin,
statin, and β-blockers were more frequently used during
hospitalization and at discharge in ACS-alone patients.
3.3. Predictors for Polyvascular Disease. Multivariate logistic
regression analysis showed that the important independent
predictors for the presence of PolyVD in ACS patients were
diabetes mellitus (adjusted OR 2.28; 95% CI 1.81–2.89),
renal failure (adjusted OR 2.32; 95% CI 1.54–3.03) and
hypertension (adjusted OR 2.66; 2.03–3.49), P = 0.001 for
all (Table 3).
3.4. Clinical Outcomes. Figure 1 demonstrates the clinical
outcomes in diﬀerent vascular disease combinations. Table 2
showshospitaloutcomesinPolyVDversusACS-alonegroup.
All primary endpoints were signiﬁcantly worse in PolyVDThe Scientiﬁc World Journal 3
Table 1:Riskfactorsandclinicalandlaboratoryﬁndingsinpatients
with acute coronary syndrome with and without polyvascular dis-
ease.
ACS alone
(n = 7261)
Polyvascular disease
(n = 428)
P
value
Age 56 ±12 62 ±12 0.001
Female 20 31 0.001
Diabetes mellitus 38 67 0.001
Hypertension 45.3 78 0.001
Dyslipidemia 36 55 0.001
Smoking 54 45 0.001
Renal failure 3 14 0.001
Prior coronary artery
disease 39 64 0.001
Prior revascularization 11 25 0.001
Khat chewing 19 20 0.92
Clinical presentation
Atypical presentation
ACS 15 28 0.001
Heart rate 84 ±20 90 ±22 0.001
Systolic blood pressure 135 ±29 140 ±35 0.01
Diastolic blood
pressure 81 ±17 79 ±20 0.02
Unstable angina 24 24
Non-STEMI 29 45 0.001
STEMI 47 31
Killip class > 1 21 45 0.001
Low GRACE risk score 41 19
0.001 High GRACE risk score 20 43
Laboratory ﬁndings
Fasting blood sugar
(mmol/L) 7.3 ±38 .1 ±3 0.001
First hemoglobin
(g/dL) 13.7 ±21 2 .5 ±2 0.001
Serum creatinine
(umol/L) 100 ±72 130 ±110 0.001
Hemoglobin A1c (%) 7.6 ±2.48 ±2.40 . 1 5
Total cholesterol
(mmol/L) 4.9 ±1.64 .4 ±1.6 0.001
Serum triglyceride
(mmol/L) 1.8 ±1.11 .6 ±0.8 0.001
Low-density
lipoprotein 3.2 ±1.32 .8 ±1.2 0.001
High-density
lipoprotein 1.05 ±0.50 .99 ±0.40 . 0 1
Peak troponin T 1.4 ±0.71 .3 ±0.60 . 0 2
LV ejection fraction
<50% 73 85 0.001
1-vessel CAD 29 48 0.001
2-vessel CAD 25 18 0.12
3-vessel CAD 30 17 0.004
All categorical and continuous variables are given in percent and mean ±
SD, respectively.
except for major bleedings. One- and 12-month all-cause
mortality was 2-times greater in PolyVD group. Univariate
analysis showed that PolyVD was predictor for reischemia,
Table 2: Management and clinical outcomes in patients with acute
coronary syndrome with and without polyvascular disease.
ACS alone
(n = 7261)
Polyvascular
disease
(n = 428)
P value
On admission therapy %
Aspirin 38 74 0.001
Clopidogrel 11 23 0.001
β-blockers 28 43.5 0.001
ACE inhibitors 24 46 0.001
Statins 29 58 0.001
Thrombolysis∗ 52 20 0.001
Unfractionated heparin 42 40 0.46
LMW heparin 37 41 0.12
Glycoprotein inhibitors 7.7 8 0.82
During hospitalization %
Aspirin 98.5 96 0.001
Clopidogrel 76 81 0.02
β blockers 75 68 0.002
ACE inhibitors 71 69 0.31
Statins 95 92.5 0.03
Coronary angiography 39 31 0.002
PCI 22 12.4 0.001
Discharge medications %
Aspirin 96 92 0.001
Clopidogrel 68 70 0.32
β blockers 80 74 0.01
ACE inhibitors 72 63.5 0.001
Statins 92 85 0.001
Outcomes %
Reischemia 15 23.4 0.001
Heart failure 11.6 29.7 0.001
Stroke 0.6 2.3 0.001
Bleedings 0.6 0.9 0.31
Hospital death 4.2 9.1 0.001
1-month death 7.4 16.3 0.001
12-month death 11.2 24.6 0.001
∗ST-elevation MI, PCI: percutaneous coronary intervention.
HF, stroke, and hospital, 1, and 12-month mortality (P =
0.001 for all). Similarly, multivariate logistic regression
analysis denoted that PolyVD was an independent predictor
for all outcomes except for major bleeding. PolyVD was
strong predictor for in-hospital stroke (adjusted OR 5.40;
95% CI 2.17–13.29, P = 0.001 Table 4 and Figure 2).
3.5. Gender and Polyvascular Disease. In comparison to their
counterparts with ACS alone, men and women with PolyVD
were older and had higher percent of commodities except for
smoking. When compared to men, women with ACS alone
hadsigniﬁcantworseoutcomesintermsofre-ischemia(18%
versus 14%), in-hospital mortality (6.3% versus 3.7%), 1-
month mortality (9.7% versus 6.8%), P = 0.001 for all. In4 The Scientiﬁc World Journal
Table 3: Multivariate logistic regression analysis for clinical pre-
dictors of polyvascular disease in patients presenting with acute
coronary syndrome.
Odds ratio (95% conﬁdence interval) P value
Age 1.04 (1.036–1.056) 0.001
Male gender 1.13 (0.865–1.466) 0.34
Dyslipidemia 1.10 (0.882–1.392) 0.37
Diabetes
mellitus 2.28 (1.809–2.889) 0.001
Hypertension 2.66 (2.028–3.489) 0.001
Smoking 1.24 (0.970–1.591) 0.07
Obesity 1.003 (0.986–1.020) 0.62
Renal failure 2.32 (1.543–3.029) 0.001
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Figure 1: Clinical outcomes in diﬀerent vascular disease combina-
tions (P = 0.001 for all comparisons).
all forms of PolyVD, there were no signiﬁcant morbidity and
mortality diﬀerences between men and women (Table 5).
Table 6 shows risk factors and in-hospital mortality in
patients with versus without polyvascular disease presenting
with acute coronary syndrome in 3 major clinical studies.
4. Discussion
The present study reports on the frequency, predictors and
implication of PolyVD in patients presenting with ACS in
the Gulf Region of the Middle East. Up to our knowledge,
PolyVD in ACS patients was not reported in the Middle
East before. There are several key ﬁndings in this study.
First, PolyVD is a common disorder in that region in the
setting of acute coronary events and represents a marker
of high-risk population. The prevalence of PolyVD in the
current study (5.6%) is over 2-fold lower versus GRACE
study(15.6%),Allianceproject(13%),andMASCARAstudy
(16.6% Table 6). Among the 4 studies, the high percent
of young age, DM, and renal failure were observed in the
current study. However, the diﬀerence in presentations and
outcomes in the 4 studies may in part relate to diversity of
biological and environmental factors between the diﬀerent
ethnicities. This observation needs further conﬁrmatory
studies. Second, PolyVD is associated with higher mortality
Age
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Diabetes mellitus
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Dyslipidemia
Renal failure
Smoking
Prior coronary artery disease
Prior revascularization
ACS (ST-elevation MI)
Polyvascular disease
Odd ratio
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ACS (ST-elevation MI)
Polyvascular disease
Odd ratio
(b)
Figure 2: Clinical predictors for in-hospital and 1-year mortality.
rate even after adjusting for baseline variables. Third,a t
presentation, those patients were more likely to have atypical
presentation, high resting heart rate, high Killip class, and
high GRACE risk score. Moreover, NSTEACS was the most
frequent diagnosis in PolyVD in comparison to ACS-alone
group. Our ﬁndings are consistent with data from Western
reports [5–9]. These studies showed that the management of
PolyVD group was less aggressive in terms of less in-hospital
coronary intervention and less evidence-based therapies
during hospitalization and at discharge [6–8]. Several factors
could explain the undertreatment trend in PolyVD group
such as high percent of comorbidities with subsequent
contraindication of some medications, physician and patient
discretion, and possible socioeconomic factors. Understand-
ing such reasons may reduce this therapy imbalance. Fourth,
the current study shows that increasing the number of
the aﬀected vascular bed is associated with the worst
clinical scenario (Figure 1). Apart from major bleedings,
PolyVD is independent predictor for all in-hospital adverse
outcomes. PolyVD increased risk of stroke 5-times even
after adjustment for other covariates. PAD increased rate
of HF and hospital mortality by 3-times whereas presence
of CVD increased rate of in-hospital stroke 4-times. Data
from Table 5 indicates that the highest mortality rate was
observed in patients with PAD in our study, in patients
with CVD in ALLIANCE project, and in patients with triple
vascular bed aﬀection in MASCARA and our study. Data
from the Japanese REACH registry [13] denoted that the
rates of 1-year stroke and myocardial infarction were higherThe Scientiﬁc World Journal 5
Table 4: Multivariate logistic regression analysis for predictors of clinical outcomes in patients with polyvascular disease presenting with
acute coronary syndrome.
Unadjusted odds ratio (95% CI) Adjusted odds ratio∗ (95% CI)
Re-ischemia 1.7 (1.37–2.15), P = 0.001 1.50 (1.12–2.01), P = 0.007
Heart failure 3.3 (2.67–4.09), P = 0.001 2.00 (1.47–2.61), P = 0.001
In-hospital Stroke 4.1 (2.03–8.22), P = 0.001 5.40 (2.17–13.29), P = 0.001
Major bleedings 1.61 (0.57–4.52), P = 0.36 1.68 (0.54–5.17), P = 0.37
Hospital death 2.3 (1.66–3.26), P = 0.001 1.85 (1.25–2.74), P = 0.01
1-month death 2.5 (1.89–3.29), P = 0.001 2.03 (1.46–2.83), P = 0.001
12-month death 2.6 (2.02–3.32), P = 0.001 1.83 (1.83–2.45), P = 0.003
CI: conﬁdence interval, ∗variables adjusted for age, sex, diabetes mellitus, hypertension, dyslipidemia, smoking, renal failure, prior coronary artery disease,
and prior coronary revascularization in addition to the type of ACS at presentation.
Table 5: Clinical proﬁles, admission therapy, and outcomes in men and women.
ACS alone Polyvascular disease
Men Women P value Men Women P value
Age (yrs, mean) 55 ±12 61 ±12 0.001 64 ±12 65 ±13 0.19
Diabetes mellitus % 35 51 0.001 63 74 0.03
Hypertension % 40.5 64 0.001 76 81 0.24
Dyslipidemia % 34 44 0.001 53 63 0.55
Smoking % 65 10 0.001 57 16 0.001
Renal failure % 3 5 0.001 16 13 0.44
Admission therapy (%)
Aspirin 98.6 98.5 0.75 96 97 0.51
Clopidogrel 79 64 0.001 82 79 0.51
Beta blockers 76 71 0.001 70 63 0.11
ACE inhibitors 71 72 0.72 70 65 0.31
H e p a r i n 5 8 5 90 . 9 84 1 3 70 . 5 0
Glycoprotein inhibitors 8.3 5.2 0.001 9 6 0.23
Statin 95 94 0.01 92 94 0.57
PCI 23 19 0.01 13 10.5 0.55
Outcomes (%)
Reischemia 14 18 0.001 21 27 0.17
Heart failure 10.7 15.5 0.001 29 34 0.28
Hospital mortality 3.7 6.3 0.001 8.6 10.8 0.46
1-month mortality 6.8 9.7 0.001 15 20 0.26
12-month mortality 10.3 15 0.001 23 29 0.22
for patients with CVD and PAD than for patients with CVD
and CAD; however, that study was not carried out during
the acute setting of coronary artery disease and did not
report on the in-hospital rate of stroke. Fifth, the present
study expands the previous reports and shows that diabetes
mellitus, hypertension, and renal failures are independent
predictorsforthepresenceofPolyVD.Thisﬁndinghighlights
the importance of primary and secondary prevention in this
high-riskpopulation.Sixth,malegenderhasbetteroutcomes
in ACS alone in comparison to female. These unfavorable
outcomes associated with female gender were shown in our
previous work as well [14]. Interestingly, presence of PolyVD
is not associated with signiﬁcant diﬀerences in the outcomes
between men and women, this ﬁnding warrants further
exploration.
5. Limitation
The current study is an observational study; however, well-
designed observational studies may provide valid results.
Another limitation of the current retrospective analysis is
that the diagnosis of PAD relied on the clinical history
and not on the measurement of ankle-brachial index (ABI).
This limitation could be explained in part by facts that6 The Scientiﬁc World Journal
Table 6:Riskfactorsandin-hospitalmortalityinpatientswithversuswithoutpolyvasculardiseasepresentingwithacutecoronarysyndrome
in diﬀerent clinical studies.
GRACE (n = 32735) [7]M A S C A R A ( n = 6745) [9]G U L F R A C E - 2 ( n = 7689) ALLIANCE (n = 8904) [6]
A
PolyVD (15.6%)
A
PolyVD (16.6%)
A
PolyVD (5.6%)
A
PolyVD (13%)
BCD B C D B CD BCD
P a t i e n t s % 8 4 7628 3 9 6 2 9 4 1 4 0 . 6 8 7 841
Age (mean yrs) 64 71 73 73 67 70 73 72 56 63 65 66 65 72
Smoking 59 69 53 68 36/28∗ 61/22∗ 44/16∗ 60/21∗ 54 54 39 62 59 63
Diabetes
mellitus 22 38 34 42 28 49 43 52 38 77 61 82 19 34
Hypertension 58 72 78 82 58 72 76 69 45 72 79 82 48 66
Dyslipidemia 46 58 52 65 46 57 50 53 36 55 53 67 43 47
Renal failure N/A N/A N/A N/A N/A N/A N/A N/A 3 20 10 30 3 12
Mortality 4.5 7.2 8.9 9.2 4.8 9.1 9.2 16 4 12 7 15 5.7 9.8 14 13
A: acute coronary syndrome (ACS) alone; B: ACS plus peripheral arterial disease (PAD); C: ACS plus cerebrovascular disease (CVD); D: ACS plus PAD plus
CVD; PolyVD: polyvascular disease, all categorical variables represents in percentage (%); DM: diabetes mellitus; N/A: data not available; ∗prior/current
smoking. Data were collected from [6, 7, 9].
clinical variables used are incompletely sensitive to identify
PAD, approximately half of subjects with ABI <0.90 are
asymptomatic, and of those that are symptomatic, only a
minority haveclassic intermittent claudication. The presence
of PolyVD is underdiagnosed in our daily practice that
may underestimate its true prevalence and impact on the
outcome.
6. Conclusion
Although PolyVD’s patients are high-risk population in
the setting of ACS, they received less aggressive therapy.
Apart from major bleedings, PolyVD is an independent
predictor for adverse hospital outcomes and short- and long-
term mortality. Great eﬀorts should be directed to primary
and secondary prevention. Looking for the other aﬀected
vascular bed in ACS patients will add an important step in
risk stratiﬁcation and management.
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